Literature DB >> 24727531

Oligonucleotide-based therapy for neurodegenerative diseases.

Iddo Magen1, Eran Hornstein2.   

Abstract

Molecular genetics insight into the pathogenesis of several neurodegenerative diseases, such as Alzheimer׳s disease, Parkinson׳s disease, Huntington׳s disease and amyotrophic lateral sclerosis, encourages direct interference with the activity of neurotoxic genes or the molecular activation of neuroprotective pathways. Oligonucleotide-based therapies are recently emerging as an efficient strategy for drug development and these can be employed as new treatments of neurodegenerative states. Here we review advances in this field in recent years which suggest an encouraging assessment that oligonucleotide technologies for targeting of RNAs will enable the development of new therapies and will contribute to preservation of brain integrity.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antisense oligonucleotides; Delivery; Neurodegeneration; RNA interference; microRNA; siRNA

Mesh:

Substances:

Year:  2014        PMID: 24727531     DOI: 10.1016/j.brainres.2014.04.005

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  20 in total

Review 1.  The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations.

Authors:  Anandita Agarwala; Peter Jones; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2015-01       Impact factor: 5.113

Review 2.  Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins.

Authors:  Maryam Tabarzad; Marzieh Jafari
Journal:  Protein J       Date:  2016-04       Impact factor: 2.371

3.  The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function.

Authors:  Nikkie F M Olde Loohuis; Nael Nadif Kasri; Jeffrey C Glennon; Hans van Bokhoven; Sébastien S Hébert; Barry B Kaplan; Gerard J M Martens; Armaz Aschrafi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-02-27       Impact factor: 5.067

4.  Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Authors:  Brian Spencer; Ivy Trinh; Edward Rockenstein; Michael Mante; Jazmin Florio; Anthony Adame; Omar M A El-Agnaf; Changyoun Kim; Eliezer Masliah; Robert A Rissman
Journal:  Neurobiol Dis       Date:  2019-03-05       Impact factor: 5.996

5.  VEGF Overexpression Significantly Increases Nanoparticle-Mediated siRNA Delivery and Target-Gene Downregulation.

Authors:  Shanshan Tan; Zhihang Chen; Yelena Mironchik; Noriko Mori; Marie-France Penet; Ge Si; Balaji Krishnamachary; Zaver M Bhujwalla
Journal:  Pharmaceutics       Date:  2022-06-14       Impact factor: 6.525

Review 6.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

7.  Synthesis of dinucleoside acylphosphonites by phosphonodiamidite chemistry and investigation of phosphorus epimerization.

Authors:  William H Hersh
Journal:  Beilstein J Org Chem       Date:  2015-01-30       Impact factor: 2.883

Review 8.  Targets for future clinical trials in Huntington's disease: what's in the pipeline?

Authors:  Edward J Wild; Sarah J Tabrizi
Journal:  Mov Disord       Date:  2014-08-25       Impact factor: 10.338

Review 9.  Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review.

Authors:  Ming Ming Wen
Journal:  Front Mol Neurosci       Date:  2016-11-22       Impact factor: 5.639

10.  Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease.

Authors:  Sepideh Parsi; Pascal Y Smith; Claudia Goupil; Véronique Dorval; Sébastien S Hébert
Journal:  Mol Ther Nucleic Acids       Date:  2015-10-06       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.